Diagnostic limitations and procedure-related implantation in follicular-patterned thyroid tumors: a focused review with two illustrative cases
- 1The Center of Breast and Thyroid Surgery, Department of General Surgery, The Affiliated Hospital of Southwest Jiaotong University, The Third People’s Hospital of Chengdu
Abstract
The rapid adoption of thyroid radiofrequency ablation (RFA) and remote-access thyroid surgery has changed the therapeutic landscape for thyroid nodules. These approaches can reduce visible scarring, shorten recovery, and offer alternatives to conventional surgery in appropriately selected patients. However, their expansion has also exposed a persistent diagnostic vulnerability: follicular-patterned thyroid tumors cannot be definitively classified as benign or malignant by cytology alone, because the diagnosis of follicular thyroid carcinoma requires histologic assessment of capsular and/or vascular invasion. This review first summarizes the current clinical context of minimally invasive thyroid intervention, the diagnostic boundaries of fine-needle aspiration and Bethesda reporting in follicular-lineage lesions, the definitions and published evidence for needle-tract or surgical-tunnel implantation, and the molecular context of DICER1-altered follicular-patterned tumors. Two implantation-related cases are used as illustrative clinical scenarios rather than as the primary evidentiary basis. The Discussion then addresses the major controversies, including procedural expansion, the role of benign cytology as a preprocedural gatekeeper, the uncertain role of molecular testing before ablation, terminology, patient selection, surveillance, research gaps, and potential developments. The available literature remains dominated by case reports and small series, and causal inference is limited. Nevertheless, repeated reports of tract- or tunnel-aligned deposits in follicular-lineage tumors suggest that implantation risk should be considered when selecting patients for ablative or remote-access interventions. Molecular alterations such as DICER1 RNase IIIb hotspot mutations may provide biological context, but they should not replace histologic classification. Future progress will require standardized reporting, prospective registries, molecularly annotated cohorts, and preprocedural algorithms that integrate imaging, cytology, molecular testing, procedural anatomy, and patient preference.
Related
- Ocular Follicular Lymphoma with Marginal Zone Differentiation: A Diagnostic Pitfall Mimicking MALT Lymphoma
- Endovascular ultrasound-guided endoprosthesis implantation for post-traumatic arteriovenous fistulas: overcoming the limitations of angiographic imaging
- Sacral spinal dural arteriovenous fistula: diagnostic pitfalls and treatment challenges. Illustrative case
- A practical approach to follicular-patterned thyroid neoplasms: Diagnostic criteria, molecular genetics, and patient management
- Advances in Diagnostic Testing for Eosinophilic Esophagitis: Current Approaches, Limitations, and Emerging Technologies
BibTeX
@article{zhang2026diagnostic,
title = {{Diagnostic limitations and procedure-related implantation in follicular-patterned thyroid tumors: a focused review with two illustrative cases}},
author = {Wenjie Zhang and Yuanyuan Chen and Jie Xiao and Ying Liu and Pin Wang and Hong Liu and Jiechao Ren and Jian Wu},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1927184},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1927184/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Diagnostic limitations and procedure-related implantation in follicular-patterned thyroid tumors: a focused review with two illustrative cases
AU - Wenjie Zhang
AU - Yuanyuan Chen
AU - Jie Xiao
AU - Ying Liu
AU - Pin Wang
AU - Hong Liu
AU - Jiechao Ren
AU - Jian Wu
PY - 2026
DA - 2026/10/21
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1927184
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1927184/full
AB - The rapid adoption of thyroid radiofrequency ablation (RFA) and remote-access thyroid surgery has changed the therapeutic landscape for thyroid nodules. These approaches can reduce visible scarring, shorten recovery, and offer alternatives to conventional surgery in appropriately selected patients. However, their expansion has also exposed a persistent diagnostic vulnerability: follicular-patterned thyroid tumors cannot be definitively classified as benign or malignant by cytology alone, because the diagnosis of follicular thyroid carcinoma requires histologic assessment of capsular and/or vascular invasion. This review first summarizes the current clinical context of minimally invasive thyroid intervention, the diagnostic boundaries of fine-needle aspiration and Bethesda reporting in follicular-lineage lesions, the definitions and published evidence for needle-tract or surgical-tunnel implantation, and the molecular context of DICER1-altered follicular-patterned tumors. Two implantation-related cases are used as illustrative clinical scenarios rather than as the primary evidentiary basis. The Discussion then addresses the major controversies, including procedural expansion, the role of benign cytology as a preprocedural gatekeeper, the uncertain role of molecular testing before ablation, terminology, patient selection, surveillance, research gaps, and potential developments. The available literature remains dominated by case reports and small series, and causal inference is limited. Nevertheless, repeated reports of tract- or tunnel-aligned deposits in follicular-lineage tumors suggest that implantation risk should be considered when selecting patients for ablative or remote-access interventions. Molecular alterations such as DICER1 RNase IIIb hotspot mutations may provide biological context, but they should not replace histologic classification. Future progress will require standardized reporting, prospective registries, molecularly annotated cohorts, and preprocedural algorithms that integrate imaging, cytology, molecular testing, procedural anatomy, and patient preference.
SN - 1664-2392
ER -